Skip to main content
AAPS PharmSciTech logoLink to AAPS PharmSciTech
. 2001 Oct 19;2(3):81–87. doi: 10.1208/pt020319

In vitro assessment of alkylglycosides as permeability enhancers

John G Eley 1,, Prasanth Triumalashetty 1
PMCID: PMC2750584  PMID: 14727878

Abstract

A series of alkylglycosides has been evaluated on human cell lines to determine its ability to open cellular tight junctions. Alkylglycosides were applied to cell monolayers; the resulting change in resistance was determined by transepithelial electrical resistance measurements. Change in resistance across cell monolayers is an indieation of tight junction activation, whereas subsequent increase in resistance signifies monolayer recovery. Of the 13 alkylglycosides tested, 4 caused irreversible solubilization of cell membranes, 5 allowed a partial recovery of the monolayer after a relatively rapid reduction in resistance, and 4 induced a decrease in resistance with more complete cell recovery. Alkylglycosides allowing extensive cell recovery after removal may indieate tight junctions activity dominance over membrane fluidity Repeated application of alkylglycosides for 6 hours lowered resistance across cells, which returned to near-normal values after a recovery period of 48 hours. A model dye was transported across the cell monolayer only in the presence of an alkylglycoside, although recovery of cells was incomplete. Activity of the alkylglycosides was unrelated to either the carbon chain length or to the carbohydrate moiety. A direct correlation was established between the concentration of applied alkylglycoside and reduction in resistance over a constant time period. Dodecylmaltoside and oetylglucoside were found to be optimal in decreasing resistance at low concentrations and allowing significant recovery of cells. Therefore these 2 alkylglycosides may be useful in facilitating drug transport across biological membranes.

Keywords: permeability enhancers, alkylglycosides, tight junctions

Full Text

The Full Text of this article is available as a PDF (132.8 KB).

References

  • 1.Moses AC, Gordon GS, Carey MC, Flier JS. Insulin administered intranasally as an insulin-bile salt aerosol: effectiveness and reproducibility in normal and diabetic subjects. Diabetes. 1989;32:1040–1047. doi: 10.2337/diabetes.32.11.1040. [DOI] [PubMed] [Google Scholar]
  • 2.Atchison JA, Grizzle WE, Pillion DJ. Colonic absorption of insulin: an in vitro and in vivo evaluation. J Pharmacol Exp Therap. 1989;248:567–572. [PubMed] [Google Scholar]
  • 3.Chiou GCY, Chuang C, Chang MS. Reduction of blood glucose concentrations with insulin eye drops. Diabetes Care. 1988;11:750–751. doi: 10.2337/diacare.11.9.750. [DOI] [PubMed] [Google Scholar]
  • 4.Saffron M, Kuwar C, Savariar C, Burham J, William F, Neckers D. A new approach to the oral administration of insulin and other peptide drugs. Science. 1986;233:1081–1084. doi: 10.1126/science.3526553. [DOI] [PubMed] [Google Scholar]
  • 5.Dimitrijevie D, Shaw AJ, Florence AT. Effects of some non-ionic surfactants on transepithelial permeability in Caco-2 cells. J Pharm Pharmacol. 2000;52(2):157–162. doi: 10.1211/0022357001773805. [DOI] [PubMed] [Google Scholar]
  • 6.Swenson ES, Milisen WB, Curatolo W. Intestinal permeability enhancement: efficiency, acute local toxicity and reversibility. Pharm Res. 1994;11(8):1132–1142. doi: 10.1023/A:1018984731584. [DOI] [PubMed] [Google Scholar]
  • 7.Gordon GS, Moses AC, Silver RD, Flier JS, Carey MG. Nasal absorption of insulin: enhancement by hydrophobie bile salts. Proc Natl Acad Sci U S A. 1985;82:7419–7423. doi: 10.1073/pnas.82.21.7419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Pontiroli AE, Alberetto M, Pajetta E, Calderara A, Pozza G. Human insulin plus sodium glycocholate in a nasal spray formulation: improved bioavailability and effectiveness in normal subjects. Diabetes Metab. 1987;13:441–443. [PubMed] [Google Scholar]
  • 9.Pillion DJ, Hosmer S, Meezan E. Dodecylmaltosidemediated nasal and ocular absorption of lyspro-insulin independence of surfactant action from multimer dissociation. Pharm Res. 1988;15(10):1637–1639. doi: 10.1023/A:1011975721569. [DOI] [PubMed] [Google Scholar]
  • 10.Pillion DJ, Bartlett JD, Meezan E, Yang M, Crain RJ, Grizzle WE. Systemic absorption of insulin delivered topically to the eye. Invest Ophthalmol Vis Sci. 1991;32:3021–3027. [PubMed] [Google Scholar]
  • 11.Murakami M, Kusanoi Y, Takada K, Muranishi S. Assessment of enhancing ability of medium-chain alkylsaccharides as new absorption enhancers in rat rectum. Int J Pharm. 1992;79:159–169. doi: 10.1016/0378-5173(92)90107-D. [DOI] [Google Scholar]
  • 12.Attwood D, Florence AT. Surfactant Systems: Their Chemistry, Pharmacy and Biology. London, UK: Chapman and Hall; 1983. pp. 88–90. [Google Scholar]
  • 13.Claude P, Goodenough D. Fracture faces of zonulae occludens from “tight” and “leaky” epithelia. J Cell Biol. 1973;58:390–400. doi: 10.1083/jcb.58.2.390. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES